Comparison of the targeting efficacy of marketed inhibitors.

<p>Each circle represents a marketed kinase inhibitor and its targeted cell growth inhibition. A: Cell lines that overexpress <i>EGFR</i>. B: Cell lines containing the <i>BRAF(V600E)</i> mutation. C: Cell lines containing aberrant <i>ABL1</i> signalling. Compounds in the upper left corner of the plots have superior targeting. Statistically relevant associations after correction for multiple testing are coloured blue. D: Quantitative comparison of inhibitor targeting by standardization of IC₅₀ shifts between sensitive and non-sensitive cell lines.